StimCardio Medical, a Los Angeles device startup, said Thursday it has closed an oversubscribed $30 million Series A, led by Metis MedTech, the family office of John Slump, to pay for a pivotal trial of a wrist-worn atrial fibrillation therapy.
Catalyst Health Ventures, "multiple corporate strategic investors" and other new and existing backers also took part, according to the company's Oct. 29 press release. The company did not disclose a valuation in the materials reviewed.
Where the money goes
Proceeds will fund NeuroPulse 2, a multicenter pivotal study that compares catheter ablation combined with wearable neuromodulation against ablation alone. The company also plans to prepare a De Novo submission to the U.S. Food and Drug Administration, the pathway for novel devices with no existing equivalent on the market.
As of Oct. 30, no ClinicalTrials.gov listing for NeuroPulse 2 was public, which leaves outsiders without the trial's design details.
"Our vision is to establish non-invasive neuromodulation as a new therapeutic category in cardiac electrophysiology," Amir Soltanianzadeh, the company's chief executive, said in the release.
A device for the wrist, not the procedure room
The product, Rhyvive, is a wrist-worn median nerve stimulator with built-in sensing for ECG, PPG (a light-based measure of blood flow) and motion, along with closed-loop analytics, according to the company's website. It is intended as a physician-prescribed, at-home companion to catheter ablation, with the aim of lowering the chance that atrial fibrillation returns afterward. The company describes the sensation as "mild tingling."
Rhyvive remains investigational. The company said U.S. law limits it to investigational use, and it is not cleared for commercial sale.
What the pilot showed
On Sept. 20, StimCardio reported results from NEUROPULSE 1, a three-center, randomized, double-blind, sham-controlled pilot. Researchers assigned 77 patients 1:1 to active stimulation or sham, and a modified intention-to-treat group of 59 remained after a 60-day blanking period, during which early arrhythmias are not counted.
The picture is mixed. The company said active stimulation produced a statistically significant reduction in recurrent atrial arrhythmia events versus sham in a post-blanking sensitivity analysis. Yet freedom from atrial arrhythmias at six months, 90.0% versus 80.8%, was not statistically significant. The company reported no stimulation- or device-related serious adverse events.
The results were presented as a late-breaker at HRX Live 2026 and published in Heart Rhythm. Vivek Y. Reddy, MD, of Mount Sinai, was lead investigator. Disclosure records from Heart Rhythm and the Heart Rhythm Society indicate that some investigators have financial relationships with StimCardio or its former name, CardiaCare.
Round history
A Form D filed with the Securities and Exchange Commission on July 29 showed a $25 million offering, with $24,949,739 sold to 80 investors under Rule 506(b). StimCardio's About page says Slump led a $25 million Series A. That figure appears to be the initial close, with the $30 million announced this week as the final tally, though the company's materials do not spell this out.
Joshua Phillips, managing partner at Catalyst Health Ventures and a StimCardio board member, said in the release: "Catalyst Health Ventures invests early in paradigm-shifting technologies with the potential to transform patient care."
The people involved
Soltanianzadeh previously co-founded and led Spine Align and founded Solardis Health Ventures. Amos Ziv is founder and chief scientific officer, and Tsahi Holand is co-founder and chief technology officer. Alexei Mlodinow, MD, chairs the board. Slump's biography on the company site lists co-founding Farapulse and a 2026 sale of Atraverse Medical to Johnson & Johnson.
StimCardio is headquartered in Los Angeles, with a technology center in Austin and scientific operations in Israel. LinkedIn lists 2 to 10 employees, though that snapshot may be out of date.
Competitive landscape
The large ablation makers, among them Boston Scientific (maker of Farapulse), Johnson & Johnson MedTech, Abbott and Medtronic, sell therapies delivered in the procedure room rather than at home. The need is real: the 2023 ACC/AHA/ACCP/HRS guideline says atrial fibrillation recurs in 30% to 40% of patients after a first ablation.
Cala Health's wrist-worn nerve stimulator is FDA-cleared for tremor, not atrial fibrillation. It offers a regulatory precedent for the form factor in other conditions.
What comes next
StimCardio said the proceeds will fund the NeuroPulse 2 pivotal study and prepare a De Novo submission to the FDA. The company also published a second pilot, BEAT-AF, in paroxysmal atrial fibrillation, in Heart Rhythm on Oct. 22.
